These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 28550080)
21. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Chiang SS; Chen JB; Yang WC Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148 [TBL] [Abstract][Full Text] [Related]
22. Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis. Zhuang B; Gan L; Liu B; Yuan W; Shi M; Peng A; Wang L; Chen X; Liu T; Zhang S; Wang S; Gao Q; Wang B; Zheng H; Liu C; Luo Y; Ye H; Lin H; Li Y; He Q; Zheng F; Luo P; Long G; Lu W; Li K; Yang J; Liu YC; Zhang Z; Li X; Zhang W; Zuo L Nephrol Dial Transplant; 2024 Sep; 39(10):1649-1661. PubMed ID: 38453435 [TBL] [Abstract][Full Text] [Related]
23. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523 [TBL] [Abstract][Full Text] [Related]
24. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
25. MgCaCO3 versus CaCO3 in peritoneal dialysis patients--a cross-over pilot trial. Evsanaa B; Liu I; Aliazardeh B; Mahdavi S; Bajwa G; Gula J; Tam M; Sze E; Roscoe JM; Tam PY; Sikaneta T Perit Dial Int; 2015; 35(1):31-4. PubMed ID: 24584605 [TBL] [Abstract][Full Text] [Related]
26. Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial. Ogata H; Fukagawa M; Hirakata H; Kagimura T; Akizawa T; Clin Exp Nephrol; 2022 Dec; 26(12):1223-1232. PubMed ID: 36064876 [TBL] [Abstract][Full Text] [Related]
27. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Joy MS; Finn WF; Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461 [TBL] [Abstract][Full Text] [Related]
28. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S; Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402 [TBL] [Abstract][Full Text] [Related]
29. Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis. Edmonston DL; Isakova T; Dember LM; Brunelli S; Young A; Brosch R; Beddhu S; Chakraborty H; Wolf M Am J Kidney Dis; 2021 Jun; 77(6):920-930.e1. PubMed ID: 33279558 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645 [TBL] [Abstract][Full Text] [Related]
31. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157 [TBL] [Abstract][Full Text] [Related]
32. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Hutchison AJ; Laville M; Nephrol Dial Transplant; 2008 Nov; 23(11):3677-84. PubMed ID: 18577536 [TBL] [Abstract][Full Text] [Related]
33. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants. Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial. Takahara Y; Matsuda Y; Takahashi S; Shigematsu T; Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863 [TBL] [Abstract][Full Text] [Related]
35. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis. Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646 [TBL] [Abstract][Full Text] [Related]
36. Phosphate Binders and Targets Over Decades: Do We have it Right Now? Marcuccilli M; Chonchol M; Jovanovich A Semin Dial; 2017 Mar; 30(2):134-141. PubMed ID: 28064444 [TBL] [Abstract][Full Text] [Related]
37. Management of phosphate abnormalities in hemodialysis patients: Findings from Malaysia. Mohamed Koya SNM Saudi J Kidney Dis Transpl; 2019; 30(3):670-677. PubMed ID: 31249232 [TBL] [Abstract][Full Text] [Related]
38. Feasibility study of colestipol as an oral phosphate binder in hemodialysis patients. Hood CJ; Wolley MJ; Kam AL; Kendrik-Jones JC; Marshall MR Nephrology (Carlton); 2015 Apr; 20(4):250-6. PubMed ID: 25557531 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212 [TBL] [Abstract][Full Text] [Related]
40. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. Bro S; Rasmussen RA; Handberg J; Olgaard K; Feldt-Rasmussen B Am J Kidney Dis; 1998 Feb; 31(2):257-62. PubMed ID: 9469496 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]